1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Europe Antibiotics & Antimycotics Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Europe Antibiotics & Antimycotics Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Europe Antibiotics & Antimycotics Market Regional Analysis
6.2 Europe Antibiotics & Antimycotics Market Revenue 2021-2031 (US$ Million)
6.3 Europe Antibiotics & Antimycotics Market Forecast Analysis
7. Europe Antibiotics & Antimycotics Market Analysis – by Drug Class
7.1 Penicillin
- 7.1.1 Overview
- 7.1.2 Penicillin: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Cephalosporines
- 7.2.1 Overview
- 7.2.2 Cephalosporines: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Carbapenems
- 7.3.1 Overview
- 7.3.2 Carbapenems: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Macrolides
- 7.4.1 Overview
- 7.4.2 Macrolides: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Aminoglycosides
- 7.5.1 Overview
- 7.5.2 Aminoglycosides: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.6 Quinolones
- 7.6.1 Overview
- 7.6.2 Quinolones: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.7 Sulfonamides
- 7.7.1 Overview
- 7.7.2 Sulfonamides: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.8 Tetracyclines
- 7.8.1 Overview
- 7.8.2 Tetracyclines: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.9 Azoles
- 7.9.1 Overview
- 7.9.2 Azoles: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.10 Others
- 7.10.1 Overview
- 7.10.2 Others: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8. Europe Antibiotics & Antimycotics Market Analysis – by Indication
8.1 Skin Infections
- 8.1.1 Overview
- 8.1.2 Skin Infections: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Respiratory Infections
- 8.2.1 Overview
- 8.2.2 Respiratory Infections: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Urinary Tract Infections
- 8.3.1 Overview
- 8.3.2 Urinary Tract Infections: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Septicemia
- 8.4.1 Overview
- 8.4.2 Septicemia: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.5 Ear Infections
- 8.5.1 Overview
- 8.5.2 Ear Infections: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Gastrointestinal Infections
- 8.6.1 Overview
- 8.6.2 Gastrointestinal Infections: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.7 Others
- 8.7.1 Overview
- 8.7.2 Others: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
9. Europe Antibiotics & Antimycotics Market Analysis – by Route Of Administration
9.1 Oral
- 9.1.1 Overview
- 9.1.2 Oral: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Topical
- 9.2.1 Overview
- 9.2.2 Topical: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Others
- 9.3.1 Overview
- 9.3.2 Others: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
10. Europe Antibiotics & Antimycotics Market Analysis – by Distribution Channel
10.1 Hospital Pharmacies
- 10.1.1 Overview
- 10.1.2 Hospital Pharmacies: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
10.2 Retail Pharmacies
- 10.2.1 Overview
- 10.2.2 Retail Pharmacies: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
10.3 Online Pharmacies
- 10.3.1 Overview
- 10.3.2 Online Pharmacies: Europe Antibiotics & Antimycotics Market – Revenue and Forecast, 2021-2031 (US$ Million)
11. Europe Antibiotics & Antimycotics Market – Europe Analysis
11.1 Overview
11.2 Europe
- 11.2.1 Europe Antibiotics & Antimycotics Market Breakdown, by Key
Country, 2024 and 2031 (%)
- 11.2.1.1 Europe Antibiotics & Antimycotics Market – Revenue and
Forecast Analysis – by Country
- 11.2.1.1 Germany:
Europe Antibiotics & Antimycotics Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.1.1 Germany: Europe Antibiotics & Antimycotics Market Breakdown, by Drug Class
- 11.2.1.1.2 Germany: Europe Antibiotics & Antimycotics Market Breakdown, by Indication
- 11.2.1.1.3 Germany: Europe Antibiotics & Antimycotics Market Breakdown, by Route Of Administration
- 11.2.1.1.4 Germany: Europe Antibiotics & Antimycotics Market Breakdown, by Distribution Channel
- 11.2.1.2 France:
Europe Antibiotics & Antimycotics Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.2.1 France: Europe Antibiotics & Antimycotics Market Breakdown, by Drug Class
- 11.2.1.2.2 France: Europe Antibiotics & Antimycotics Market Breakdown, by Indication
- 11.2.1.2.3 France: Europe Antibiotics & Antimycotics Market Breakdown, by Route Of Administration
- 11.2.1.2.4 France: Europe Antibiotics & Antimycotics Market Breakdown, by Distribution Channel
- 11.2.1.3 Italy:
Europe Antibiotics & Antimycotics Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.3.1 Italy: Europe Antibiotics & Antimycotics Market Breakdown, by Drug Class
- 11.2.1.3.2 Italy: Europe Antibiotics & Antimycotics Market Breakdown, by Indication
- 11.2.1.3.3 Italy: Europe Antibiotics & Antimycotics Market Breakdown, by Route Of Administration
- 11.2.1.3.4 Italy: Europe Antibiotics & Antimycotics Market Breakdown, by Distribution Channel
- 11.2.1.4 UK:
Europe Antibiotics & Antimycotics Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.4.1 UK: Europe Antibiotics & Antimycotics Market Breakdown, by Drug Class
- 11.2.1.4.2 UK: Europe Antibiotics & Antimycotics Market Breakdown, by Indication
- 11.2.1.4.3 UK: Europe Antibiotics & Antimycotics Market Breakdown, by Route Of Administration
- 11.2.1.4.4 UK: Europe Antibiotics & Antimycotics Market Breakdown, by Distribution Channel
- 11.2.1.5 Spain:
Europe Antibiotics & Antimycotics Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.5.1 Spain: Europe Antibiotics & Antimycotics Market Breakdown, by Drug Class
- 11.2.1.5.2 Spain: Europe Antibiotics & Antimycotics Market Breakdown, by Indication
- 11.2.1.5.3 Spain: Europe Antibiotics & Antimycotics Market Breakdown, by Route Of Administration
- 11.2.1.5.4 Spain: Europe Antibiotics & Antimycotics Market Breakdown, by Distribution Channel
- 11.2.1.6 Rest of Europe:
Europe Antibiotics & Antimycotics Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.6.1 Rest of Europe: Europe Antibiotics & Antimycotics Market Breakdown, by Drug Class
- 11.2.1.6.2 Rest of Europe: Europe Antibiotics & Antimycotics Market Breakdown, by Indication
- 11.2.1.6.3 Rest of Europe: Europe Antibiotics & Antimycotics Market Breakdown, by Route Of Administration
- 11.2.1.6.4 Rest of Europe: Europe Antibiotics & Antimycotics Market Breakdown, by Distribution Channel
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 Pfizer Inc
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Novartis AG
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Sanofi SA
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 F. Hoffmann-La Roche Ltd
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Merck & Co Inc
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 GSK Plc
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Johnson & Johnson
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Cipla Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Bayer AG
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 AbbVie Inc
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
14.11 Astellas Pharma Inc
- 14.11.1 Key Facts
- 14.11.2 Business Description
- 14.11.3 Products and Services
- 14.11.4 Financial Overview
- 14.11.5 SWOT Analysis
- 14.11.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations